-+ 0.00%
-+ 0.00%
-+ 0.00%

Wolfe Research Downgrades Corcept Therapeutics to Underperform, Announces $50 Price Target

Benzinga·07/27/2026 11:59:37
Listen to the news
Wolfe Research analyst Kalpit Patel downgrades Corcept Therapeutics (NASDAQ:CORT) from Peer Perform to Underperform and announces $50 price target.